Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Renal Cell
/ drug therapy
Disease Progression
Female
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Kidney Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Male
Melanoma
/ drug therapy
Middle Aged
Retrospective Studies
Steroids
/ therapeutic use
Survival Analysis
Treatment Outcome
biomarkers
immune checkpoint inhibitors
immunotherapy
irAEs
melanoma
non-small cell cancer
renal cell cancer
steroid
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
24 Sep 2021
24 Sep 2021
Historique:
received:
13
05
2021
revised:
15
09
2021
accepted:
15
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Immune-related adverse events (irAEs) are inflammatory side effects, which can occur during immune-checkpoint(s) inhibitors (ICIs) therapy. Steroids are the first-line agents to manage irAEs because of their immunosuppressive properties. However, it is still debated whether or when steroids can be administered without abrogating the therapeutic efforts of immunotherapy. We retrospectively evaluated 146 patients with metastatic non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC) treated with ICIs. We assessed the progression-free survival (PFS) of patients treated with steroids due to an irAE compared to a no-steroid group. The early treatment with steroid (within the first 30 days from the beginning of immunotherapy) was not related to a shorter PFS ( This retrospective study points out that early systemic steroids administration to manage irAEs might not have a detrimental effect on patient clinical outcome in NSCLC, melanoma and RCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Immune-related adverse events (irAEs) are inflammatory side effects, which can occur during immune-checkpoint(s) inhibitors (ICIs) therapy. Steroids are the first-line agents to manage irAEs because of their immunosuppressive properties. However, it is still debated whether or when steroids can be administered without abrogating the therapeutic efforts of immunotherapy.
METHODS
METHODS
We retrospectively evaluated 146 patients with metastatic non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC) treated with ICIs. We assessed the progression-free survival (PFS) of patients treated with steroids due to an irAE compared to a no-steroid group.
RESULTS
RESULTS
The early treatment with steroid (within the first 30 days from the beginning of immunotherapy) was not related to a shorter PFS (
CONCLUSIONS
CONCLUSIONS
This retrospective study points out that early systemic steroids administration to manage irAEs might not have a detrimental effect on patient clinical outcome in NSCLC, melanoma and RCC patients.
Identifiants
pubmed: 34641331
pii: molecules26195789
doi: 10.3390/molecules26195789
pmc: PMC8510096
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Steroids
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2002 Jun;8(6):1681-94
pubmed: 12060604
Front Oncol. 2017 Apr 03;7:56
pubmed: 28421161
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Oncoimmunology. 2018 Sep 6;7(12):e1500108
pubmed: 30524891
J Clin Oncol. 2014 Oct 10;32(29):3221-8
pubmed: 25002731
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Oncoimmunology. 2020 Oct 5;9(1):1824645
pubmed: 33101774
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33154150
J Thorac Oncol. 2018 Nov;13(11):1771-1775
pubmed: 29935305
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Eur J Immunol. 2006 Aug;36(8):2139-49
pubmed: 16841298
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9573-8
pubmed: 10920190
Eur J Cancer. 2020 Dec;141:239-251
pubmed: 33212339
BMC Immunol. 2015 Jun 26;16:39
pubmed: 26112261
J Neurooncol. 2010 Jan;96(1):103-14
pubmed: 19957014
J Clin Oncol. 2019 Aug 1;37(22):1927-1934
pubmed: 31206316
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
J Palliat Med. 2012 Jul;15(7):834-7
pubmed: 22385025
J Neuroendocrinol. 2018 Feb;30(2):
pubmed: 29024170
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630154
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
JAMA. 2017 Nov 7;318(17):1647-1648
pubmed: 28885639
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007977
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13
pubmed: 20398732
Front Immunol. 2016 Dec 19;7:604
pubmed: 28066415
Cancers (Basel). 2021 Feb 18;13(4):
pubmed: 33670634
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Arthritis Rheum. 2006 Feb;54(2):628-34
pubmed: 16447241
Cell Rep. 2014 May 22;7(4):938-9
pubmed: 24856295
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126